Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
Represents total equity value of up to approximately $1.1 billion
ANN ARBOR, Mich., Ma... [14330 chars]